The KM curves, which are unadjusted for other prognostic factors, suggest that patients receiving a BRAF inhibitor after diagnosis of brain metastases had better survival outcomes than patients with BRAF mutant tumours who did not receive this treatment (log-rank test P=0.029). This evidence concerns the gene BRAF and neoplasm.